Skip to main content

Advertisement

SpringerLink
Log in

The clinical and prognostic significance of midkine in breast cancer patients

  • Research Article
  • Published:
Tumor Biology

Abstract

Midkine overexpression has been shown to be a tumor biomarker in several types of human cancer, but little is known about the clinical significance of midkine in breast cancer patients. The aim of this study was to analyze the expression of midkine in breast cancer and its correlation with clinicopathological characteristics, including breast cancer patient’s survival. The expression status of midkine in breast cancer from Gene Expression Omnibus (GEO accession number: GDS3853) was observed initially. Furthermore, the expression of midkine messenger RNA (mRNA) and protein was examined in breast cancer and normal mammary tissues through real-time PCR and immunohistochemistry. Moreover, the relationship of midkine protein expression with clinical characteristics of 170 breast cancer patients was analyzed by immunohistochemistry. In our results, midkine was up-expressed in breast cancer tissues compared with normal mammary tissues in microarray data (GDS3853). Midkine mRNA and protein expression was significantly increased in breast cancer tissues than in normal mammary tissues. By immunohistochemistry, high levels of midkine protein were positively associated with the status of clinical stage, T classification, N classification, and M classification in breast cancer patients. Furthermore, midkine overexpression was an independent poor prognostic indicator for the survival of patients with breast cancer. In conclusion, overexpression of midkine protein serves as an unfavorable prognostic biomarker in breast cancer patients.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1
Fig. 2
Fig. 3
Fig. 4

Similar content being viewed by others

References

  1. Allemani C, Weir HK, Carreira H, Harewood R, Spika D, Wang XS, et al. Global surveillance of cancer survival 1995-2009: analysis of individual data for 25,676,887 patients from 279 population-based registries in 67 countries (CONCORD-2). Lancet. 2015;385:977–1010.

    Article  PubMed  Google Scholar 

  2. Lu J, Steeg PS, Price JE, Krishnamurthy S, Mani SA, Reuben J, et al. Breast cancer metastasis: challenges and opportunities. Cancer Res. 2009;69:4951–3.

    Article  CAS  PubMed  Google Scholar 

  3. Siegel RL, Miller KD, Jemal A. Cancer statistics, 2015. CA Cancer J Clin. 2015;65:5–29.

    Article  PubMed  Google Scholar 

  4. Bombonati A, Sgroi DC. The molecular pathology of breast cancer progression. J Pathol. 2011;223:307–17.

    Article  CAS  PubMed  Google Scholar 

  5. Murasugi A, Tohma-Aiba Y. Production of native recombinant human midkine in the yeast, Pichia pastoris. Protein Expr Purif. 2003;27:244–52.

    Article  CAS  PubMed  Google Scholar 

  6. Kadomatsu K, Muramatsu T. Midkine and pleiotrophin in neural development and cancer. Cancer Lett. 2004;204:127–43.

    Article  CAS  PubMed  Google Scholar 

  7. Qi M, Ikematsu S, Maeda N, Ichihara-Tanaka K, Sakuma S, Noda M, et al. Haptotactic migration induced by midkine. Involvement of protein-tyrosine phosphatase zeta. Mitogen-activated protein kinase, and phosphatidylinositol 3-kinase. J Biol Chem. 2001;276:15868–75.

    Article  CAS  PubMed  Google Scholar 

  8. Muramatsu T. Midkine and pleiotrophin: two related proteins involved in development, survival, inflammation and tumorigenesis. J Biochem. 2002;132:359–71.

    Article  CAS  PubMed  Google Scholar 

  9. Choudhuri R, Zhang HT, Donnini S, Ziche M, Bicknell R. An angiogenic role for the neurokines midkine and pleiotrophin in tumorigenesis. Cancer Res. 1997;57:1814–9.

    CAS  PubMed  Google Scholar 

  10. Kadomatsu K, Hagihara M, Akhter S, Fan QW, Muramatsu H, Muramatsu T. Midkine induces the transformation of NIH3T3 cells. Br J Cancer. 1997;75:354–9.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  11. Ota K, Fujimori H, Ueda M, Shiniriki S, Kudo M, Jono H, et al. Midkine as a prognostic biomarker in oral squamous cell carcinoma. Br J Cancer. 2008;99:655–62.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  12. Aridome K, Tsutsui J, Takao S, Kadomatsu K, Ozawa M, Aikou T, et al. Increased midkine gene expression in human gastrointestinal cancers. Jpn J Cancer Res. 1995;86:655–61.

    Article  CAS  PubMed  Google Scholar 

  13. Ye C, Qi M, Fan QW, Ito K, Akiyama S, Kasai Y, et al. Expression of midkine in the early stage of carcinogenesis in human colorectal cancer. Br J Cancer. 1999;79:179–84.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  14. Kato M, Shinozawa T, Kato S, Awaya A, Terada T. Increased midkine expression in hepatocellular carcinoma. Arch Pathol Lab Med. 2000;124:848–52.

    CAS  PubMed  Google Scholar 

  15. Kato M, Shinozawa T, Kato S, Endo K, Terada T. Increased midkine expression in intrahepatic cholangiocarcinoma: immunohistochemical and in situ hybridization analyses. Liver. 2000;20:216–21.

    Article  CAS  PubMed  Google Scholar 

  16. Ma Z, Li H, Wang B, Shen Q, Cui E, Min L, et al. Midkine mRNA level in peripheral blood mononuclear cells is a novel biomarker for primary non-small cell lung cancer: a prospective study. J Cancer Res Clin Oncol. 2013;139:557–62.

    Article  CAS  PubMed  Google Scholar 

  17. Kato M, Maeta H, Kato S, Shinozawa T, Terada T. Immunohistochemical and in situ hybridization analyses of midkine expression in thyroid papillary carcinoma. Mod Pathol. 2000;13:1060–5.

    Article  CAS  PubMed  Google Scholar 

  18. Hidaka H, Yagasaki H, Takahashi Y, Hama A, Nishio N, Tanaka M, et al. Increased midkine gene expression in childhood B-precursor acute lymphoblastic leukemia. Leuk Res. 2007;31:1045–51.

    Article  CAS  PubMed  Google Scholar 

  19. Moon HS, Park WI, Sung SH, Choi EA, Chung HW, Woo BH. Immunohistochemical and quantitative competitive PCR analyses of midkine and pleiotrophin expression in cervical cancer. Gynecol Oncol. 2003;88:289–97.

    Article  CAS  PubMed  Google Scholar 

  20. Nakanishi T, Kadomatsu K, Okamoto T, Tomoda Y, Muramatsu T. Expression of midkine and pleiotropin in ovarian tumors. Obstet Gynecol. 1997;90:285–90.

    Article  CAS  PubMed  Google Scholar 

  21. Konishi N, Nakamura M, Nakaoka S, Hiasa Y, Cho M, Uemura H, et al. Immunohistochemical analysis of midkine expression in human prostate carcinoma. Oncology. 1999;57:253–7.

    Article  CAS  PubMed  Google Scholar 

  22. Luo W, Li S, Peng B, Ye Y, Deng X, Yao K. Embryonic stem cells markers SOX2, OCT4 and Nanog expression and their correlations with epithelial-mesenchymal transition in nasopharyngeal carcinoma. PLoS One. 2013;8, e56324.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  23. Muramatsu T. Midkine, a heparin-binding cytokine with multiple roles in development, repair and diseases. Proce Jpn Acad Ser B Phys Biolog Sci. 2010;86:410–25.

    Article  CAS  Google Scholar 

  24. Ikematsu S, Yano A, Aridome K, Kikuchi M, Kumai H, Nagano H, et al. Serum midkine levels are increased in patients with various types of carcinomas. Br J Cancer. 2000;83:701–6.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  25. Ibusuki M, Fujimori H, Yamamoto Y, Ota K, Ueda M, Shinriki S, et al. Midkine in plasma as a novel breast cancer marker. Cancer Sci. 2009;100:1735–9.

    Article  CAS  PubMed  Google Scholar 

  26. Kretschmer C, Sterner-Kock A, Siedentopf F, Schoenegg W, Schlag PM, Kemmner W. Identification of early molecular markers for breast cancer. Mol Cancer. 2011;10:15.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  27. Qin Li L, Huang HL, Ping JL, Xu W, Li J, Dai LC. Expression of midkine and endoglin in breast carcinomas with different immunohistochemical profiles. APMIS. 2011;119:103–10.

    Article  PubMed  Google Scholar 

  28. Shimada H, Nabeya Y, Tagawa M, Okazumi S, Matsubara H, Kadomatsu K, et al. Preoperative serum midkine concentration is a prognostic marker for esophageal squamous cell carcinoma. Cancer Sci. 2003;94:628–32.

    Article  CAS  PubMed  Google Scholar 

  29. Zhu WW, Guo JJ, Guo L, Jia HL, Zhu M, Zhang JB, et al. Evaluation of midkine as a diagnostic serum biomarker in hepatocellular carcinoma. Clin Cancer Res. 2013;19:3944–54.

    Article  CAS  PubMed  Google Scholar 

  30. Ota K, Fujimori H, Ueda M, Jono H, Shinriki S, Ota T, et al. Midkine expression is correlated with an adverse prognosis and is down-regulated by p53 in oral squamous cell carcinoma. Int J Oncol. 2010;37:797–804.

    CAS  PubMed  Google Scholar 

  31. Zhao ZQ, Yang S, Lu HS. Expression of midkine and vascular endothelial growth factor in gastric cancer and the association of high levels with poor prognosis and survival. Mol Med Rep. 2012;5:415–9.

    CAS  PubMed  Google Scholar 

Download references

Conflicts of interest

None

Author information

Authors and Affiliations

  1. Department of General Surgery, The Central Hospital of Ankang City, Ankang, Shanxi, 725000, China

    Fuguang Li & Jun Zhang

  2. Department of Hematology, The Central Hospital of Ankang City, Ankang, Shanxi, 725000, China

    Peijun Tian

  3. Department of Oncology, The Central Hospital of Ankang City, Ankang, Shanxi, 725000, China

    Changyuan Kou

Authors
  1. Fuguang Li
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Peijun Tian
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Jun Zhang
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Changyuan Kou
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Changyuan Kou.

Additional information

Fuguang Li and Peijun Tian are co-first authors.

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Li, F., Tian, P., Zhang, J. et al. The clinical and prognostic significance of midkine in breast cancer patients. Tumor Biol. 36, 9789–9794 (2015). https://doi.org/10.1007/s13277-015-3710-x

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s13277-015-3710-x

Keywords

Search

Navigation